Specialty Pharmacy

Lorlatinib approved for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib (Xalkori) and at least 1 other ALK inhibitor for metastatic disease.

Officials with the FDA have approved Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

Clobazam oral film (Sympazan) is the first and only FDA-approved oral film formulation to treat seizures associated with Lennox-Gastaut syndrome.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

Tanezumab (Eli Lilly and Pfizer) reduced osteoarthritis pain by 50% or greater in more than half of patients in a study.

Top news of the day from across the health care landscape.

All-oral direct-acting antivirals had a significant effect on the clinical and economic outcomes of patients with hepatitis C virus in the 4 years following the approval of these treatments.

Phase 2b study results show durable responses rates and symptom improvement in patients with psoriatic arthritis.

Adalimumab-adaz (Hyrimoz), a biosimilar of Humira, is the third FDA-approved Sandoz biosimilar in the United States.

Health systems and manufacturers need to work together to obtain inclusion for health system specialty pharmacies so that patients can fill their prescriptions within a coordinated care ecosystem.

This approval marks the first anti-PD-1 regimen for the first-line treatment of squamous non-small cell lung cancer regardless of tumor expression status.

Hepatitis B virus infectivity can remain stable for up to 9 months and demonstrate high resilience to antiseptics.

Preliminary data show that treatment with anti-PD-1 inhibitors may be feasible in patients with HIV and cancer.

Top news of the day from across the health care landscape.

Officials with the US FDA have approved canagliflozin (Invokana, Janssen) to reduce the risk of major adverse cardiovascular (CV) events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease.

Under the proposed plan, Medicare payments for Part B drugs would be based on international prices.

Top news of the day from across the health care landscape.

Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis.

Bijuva (estradiol and progesterone) is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.

New data show a survival benefit with pembrolizumab (Keytruda) as both a monotherapy and combination treatment with chemotherapy.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses how collaboration with manufacturers can help specialty pharmacies prepare from a patient services and distribution perspective.

Top news of the day from across the health care landscape.

Officials with the FDA have approved Jazz Pharmaceuticals' Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years with narcolepsy.

Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.

Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.